Febuxostat Apexbio

Febuxostat

A5926-100 100 mg
EUR 595
Description: IC50: Febuxostat displayed potent mixed-type inhibition of the activity of xanthine oxidase (XO), with Ki value of 0.6 nM [1]. Febuxostat was also reported to be 1000-fold (IC50=1.8 nM) more potent than allopurinol (IC50= 2.9 ?M) at inhibiting XO-dependent uric acid formation [2].

Apexbio Reagents Laboratories manufactures the febuxostat apexbio reagents distributed by Genprice. The Febuxostat Apexbio reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Apexbio Reagents. Other Febuxostat products are available in stock. Specificity: Febuxostat Category: Apexbio

Danazol

100 mg
EUR 110
Description: Danazol showed weak androgenic effects.Danazol is a derivative of testosterone and ethisterone. An androgen is any natural or synthetic agent stimulating or controling the development and maintenance of male characteristics by binding to androgen receptors.

Danazol

250 mg
EUR 187
Description: Danazol showed weak androgenic effects.Danazol is a derivative of testosterone and ethisterone. An androgen is any natural or synthetic agent stimulating or controling the development and maintenance of male characteristics by binding to androgen receptors.

Danazol

500 mg
EUR 312
Description: Danazol showed weak androgenic effects.Danazol is a derivative of testosterone and ethisterone. An androgen is any natural or synthetic agent stimulating or controling the development and maintenance of male characteristics by binding to androgen receptors.

ML-211

1 mg
EUR 112
Description: IC50: LYPLA1 (17 nM) and the related LYPLA2 (30 nM)ML-211 is a dual inhibitor of LYPLA1 and the related LYPLA2.Lysophospholipase 1 (LYPLA1), a protein palmitoyl thioesterase, is responsible for depalmitoylation of the oncogene HRas.

ML-211

10 mg
EUR 270
Description: IC50: LYPLA1 (17 nM) and the related LYPLA2 (30 nM)ML-211 is a dual inhibitor of LYPLA1 and the related LYPLA2.Lysophospholipase 1 (LYPLA1), a protein palmitoyl thioesterase, is responsible for depalmitoylation of the oncogene HRas.

ML-211

25 mg
EUR 519
Description: IC50: LYPLA1 (17 nM) and the related LYPLA2 (30 nM)ML-211 is a dual inhibitor of LYPLA1 and the related LYPLA2.Lysophospholipase 1 (LYPLA1), a protein palmitoyl thioesterase, is responsible for depalmitoylation of the oncogene HRas.

ML-211

5 mg
EUR 174
Description: IC50: LYPLA1 (17 nM) and the related LYPLA2 (30 nM)ML-211 is a dual inhibitor of LYPLA1 and the related LYPLA2.Lysophospholipase 1 (LYPLA1), a protein palmitoyl thioesterase, is responsible for depalmitoylation of the oncogene HRas.

Human Samples information

Beta-Amyloid (1-11)

A1002-25 25 mg
EUR 415
Description: Beta-amyloid (1-11) (Abeta or A?) (C56H76N16O22) is a peptide with the sequence H-{Asp}{Ala}{Glu}{Phe}{Arg}{His}{Asp}{Ser}{Gly}{Tyr}{Glu}-OH,which is processed from the Amyloid precursor protein.

Beta-Amyloid (1-11)

A1002-5 5 mg
EUR 206
Description: Beta-amyloid (1-11) (Abeta or A?) (C56H76N16O22) is a peptide with the sequence H-{Asp}{Ala}{Glu}{Phe}{Arg}{His}{Asp}{Ser}{Gly}{Tyr}{Glu}-OH,which is processed from the Amyloid precursor protein.

Amyloid ?-Protein (1-15)

A1003-1 1 mg
EUR 113
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid ?-Protein (1-15)

A1003-10 10 mg
EUR 369
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid ?-Protein (1-15)

A1003-25 25 mg
EUR 496
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid ?-Protein (1-15)

A1003-5 5 mg
EUR 241
Description: Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.

Amyloid Precursor C-Terminal Peptide

A1004-1 1 mg
EUR 113
Description: Amyloid precursor c-terminal peptide (APP) (C86H118N20O27S) has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. Although it has been implicated as a regulator of synapse formation, neural plasticity and iron export, the primary function of APP is not known.

Amyloid Precursor C-Terminal Peptide

A1004-10 10 mg
EUR 369
Description: Amyloid precursor c-terminal peptide (APP) (C86H118N20O27S) has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. Although it has been implicated as a regulator of synapse formation, neural plasticity and iron export, the primary function of APP is not known.

Amyloid Precursor C-Terminal Peptide

A1004-25 25 mg
EUR 496
Description: Amyloid precursor c-terminal peptide (APP) (C86H118N20O27S) has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. Although it has been implicated as a regulator of synapse formation, neural plasticity and iron export, the primary function of APP is not known.

Amyloid Precursor C-Terminal Peptide

A1004-5 5 mg
EUR 241
Description: Amyloid precursor c-terminal peptide (APP) (C86H118N20O27S) has the amino acid sequence Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-Gln-Asn. Although it has been implicated as a regulator of synapse formation, neural plasticity and iron export, the primary function of APP is not known.

Beta-Sheet Breaker Peptide iA?5

A1005-10 10 mg
EUR 137
Description: Beta-Sheet Breaker Peptide iA?5 (C33H43N5O8), with the sequence H-Leu-Pro-Phe-Phe-Asp-OH, has been shown to inhibit amyloidogenesis in rat brain models.

Beta-Sheet Breaker Peptide iA?5

A1005-25 25 mg
EUR 171
Description: Beta-Sheet Breaker Peptide iA?5 (C33H43N5O8), with the sequence H-Leu-Pro-Phe-Phe-Asp-OH, has been shown to inhibit amyloidogenesis in rat brain models.

Beta-Sheet Breaker Peptide iA?5

A1005-5 5 mg
EUR 102
Description: Beta-Sheet Breaker Peptide iA?5 (C33H43N5O8), with the sequence H-Leu-Pro-Phe-Phe-Asp-OH, has been shown to inhibit amyloidogenesis in rat brain models.

Angiotensin I (human, mouse, rat)

A1006-10 10 mg
EUR 166
Description: Angiotensin I (Ang I) (C62H89N17O14), with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, is formed by the action of renin on angiotensinogen.

Angiotensin I (human, mouse, rat)

A1006-25 25 mg
EUR 212
Description: Angiotensin I (Ang I) (C62H89N17O14), with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, is formed by the action of renin on angiotensinogen.

Angiotensin I (human, mouse, rat)

A1006-5 5 mg
EUR 119
Description: Angiotensin I (Ang I) (C62H89N17O14), with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, is formed by the action of renin on angiotensinogen.

Angiotensin 1/2 (1-9)

A1007-10 10 mg
EUR 166
Description: Angiotensin I/II (1-9) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS) containing the amino acids 1-9 that are converted from Angiotensin I/II peptide.